| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
The collaboration with TCGLS willfocus on a novel, undisclosed target with the expectation of finding a"new class of molecules," the company states. Under the terms of theagreement, TCGLS will contribute its expertise in the discovery andoptimization of lead compounds, while Debiopharm will provide drugdevelopment expertise and fund the development program.
DebiopharmGroup in-licenses, develops and/or co-develops promising biological andsmall-molecule drug candidates. The products are out-licensed topharmaceutical partners for sales and marketing. Debiopharm is alsoactive in the field of companion diagnostics. Debiopharm independentlyfunds the worldwide development of all of its products while providingexpertise in preclinical and clinical trials, manufacturing, drugdelivery and formulation and regulatory affairs.
Antibioticsrepresent a new strategic therapeutic area for Debiopharm. Debiopharmhas been active in India since 2006, and the company notes that it hasestablished a strong network in the country, including all of the majorplayers in drug discovery. In its new focus on antibiotics, Debiopharm'sgoal is to become a key participant in the area of antibacterials tofulfill the increasing need for new classes of antibiotics to overcomeresistance to current treatment.
"We foresee increasing ourcommitment in this field over next few months through additionalpartnerships and investments in other innovative targets," says DavidDeperthes, Debiopharm's vice president of business development andlicensing. "We are very enthusiastic about this partnership with TCGLSfor the development of novel antibiotics. Their extensive experience inmedicinal chemistry and infectious diseases is a major asset for thedevelopment of Debio 1348," which is listed on the company's website asbeing in early discovery for infectious diseases aimed at an "innovativetarget."
TCGLS started operations in 2001 in India and iscurrently active in the United States, Europe, Japan and Australia andemploys more than 800 scientists.
"We are indeed excited aboutthis program which involves a challenging new target to potentiallyaddress the vast incidence of nosocomial infections that plaguehealthcare facilities all over the world," says Swapan Bhattacharya,managing director of TCGLS. "Debiopharm's developmental expertise,combined with our medicinal chemistry capabilities and efficientdiscovery operations, provide an attractive opportunity for accelerateddiscovery of novel drug candidates for clinical development."
TheCenters for Disease Control (CDC) estimates that each year, nearly 2million people in the United States acquire an infection while in ahospital, resulting in 90,000 deaths. More than 70 percent of thebacteria that cause these infections are resistant to at least one ofthe antibiotics commonly used to treat them. The European CDC statesthat at least 25,000 patients in the EU die each year from infectionsdue to bacteria that are resistant to a number of marketed drugs.
Loading Next Article...
Loading Next Article...
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The crucial role of sample preparation in biotherapy manufacturing
Discover how better sample preparation can unlock improved assay accuracy and analytical results.
Discovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Accelerating RNA therapeutic testing with liver microphysiological platforms
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
